Explore the categories so you can find more about your search.

Categorie > Cancer / Oncology

Obesity-Related Cancer On The Rise

Categorie : Cancer / Oncology
As Americans' collective waistline has continued to expand, so has the prevalence of obesity-related cancer.According to the June issue of Mayo Clinic Health Letter, an estimated 14 percent of cancer deaths in older men and 20 percent in older women can be attributed to excess body fat. It's not ful ...

read more As Americans' collective waistline has continued to expand, so has the prevalence of obesity-related cancer.According to the June issue of Mayo Clinic Health Letter, an estimated 14 percent of cancer deaths in older men and 20 percent in older women can be attributed to excess body fat. It's not ful read more Thu Jun 2008 Thu Jun 2008

Melanoma Risk - People Obey Screening Recommendations Better After Genetic Testing - Whether Or Not They Test Positive, Study

Categorie : Cancer / Oncology
When people know the results of genetic tests confirming they have inherited an increased risk of developing melanoma, they follow skin cancer screening recommendations more proactively - much like those who have already been diagnosed with the potentially deadly disease, according to results of a s ...

read more When people know the results of genetic tests confirming they have inherited an increased risk of developing melanoma, they follow skin cancer screening recommendations more proactively - much like those who have already been diagnosed with the potentially deadly disease, according to results of a s read more Thu Jun 2008 Thu Jun 2008

Champions Biotechnology Begins Preclinical Development Of Its Lead Oncology Drug Candidate

Categorie : Cancer / Oncology
Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, announced that it has begun preclinical development of the lead Benzoylphenylurea (BPU) sulfur analog c ...

read more Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, announced that it has begun preclinical development of the lead Benzoylphenylurea (BPU) sulfur analog c read more Thu Jun 2008 Thu Jun 2008

EMEA Recommends Information On Lung Cancer Cases To Be Included In Exubera Product Information, Europe

Categorie : Cancer / Oncology
The European Medicines Agency (EMEA) has recommended that the product information for Exubera be updated with new information on cases of lung cancer seen in patients taking the medicine. Exubera, from Pfizer Limited, is a fast-acting insulin powder for inhalation, used for the treatment of adults w ...

read more The European Medicines Agency (EMEA) has recommended that the product information for Exubera be updated with new information on cases of lung cancer seen in patients taking the medicine. Exubera, from Pfizer Limited, is a fast-acting insulin powder for inhalation, used for the treatment of adults w read more Thu Jun 2008 Thu Jun 2008

Naviscan's PEM Flex? Detects Smallest Cancers Better Compared To MRI In An Independent Study

Categorie : Cancer / Oncology
Naviscan PET Systems®, a company specializing in organ specific high resolution PET scanners, announced today at the Society of Nuclear Medicine - new clinical data using the PEM Flex scanner in breast cancer management. The PEM Flex? Solo II is a commercially available, FDA cleared scanner that ut ...

read more Naviscan PET Systems®, a company specializing in organ specific high resolution PET scanners, announced today at the Society of Nuclear Medicine - new clinical data using the PEM Flex scanner in breast cancer management. The PEM Flex? Solo II is a commercially available, FDA cleared scanner that ut read more Thu Jun 2008 Thu Jun 2008

Feds Crack Down On Fake Cancer Cures

Categorie : Cancer / Oncology
The US Food and Drug Administration (FDA) is cracking down on individuals and companies that market treatment products while fraudulently claiming them to be effective at preventing, treating or curing cancer. The FDA, a federal agency in the US government's executive Department of Health and Huma ...

read more The US Food and Drug Administration (FDA) is cracking down on individuals and companies that market treatment products while fraudulently claiming them to be effective at preventing, treating or curing cancer. The FDA, a federal agency in the US government's executive Department of Health and Huma read more Thu Jun 2008 Thu Jun 2008

New Therapy Shows Promise For Fighting Treatment-Resistant Cancer Cells

Categorie : Cancer / Oncology
A gene radiotherapy system that detects and treats cancer cells that are resistant to traditional forms of chemotherapy and radiation showed success in the laboratory and could eventually prove beneficial for cancer patients, according to researchers at SNM's 55th Annual Meeting. The new system targ ...

read more A gene radiotherapy system that detects and treats cancer cells that are resistant to traditional forms of chemotherapy and radiation showed success in the laboratory and could eventually prove beneficial for cancer patients, according to researchers at SNM's 55th Annual Meeting. The new system targ read more Thu Jun 2008 Thu Jun 2008

Potential Of Targeted Therapies For Cancer

Categorie : Cancer / Oncology
A new study, presented at the SNM 55th Annual Meeting, shows the potential to pre-target the treatment of cancer cells - bringing personalized medicine one step closer from the laboratory to patients. By combining new molecular imaging techniques with targeted therapy, pretargeting offers cancer pat ...

read more A new study, presented at the SNM 55th Annual Meeting, shows the potential to pre-target the treatment of cancer cells - bringing personalized medicine one step closer from the laboratory to patients. By combining new molecular imaging techniques with targeted therapy, pretargeting offers cancer pat read more Thu Jun 2008 Thu Jun 2008

PET/CT Scan Could Be Valuable Noninvasive Tool For Determining Stages Of Ovarian Cancer

Categorie : Cancer / Oncology
Combined positron emission tomography (PET) and computed tomography (CT) scanning of patients in the early stages of ovarian cancer can enable physicians to determine whether the cancer has spread to nearby lymph nodes without having to perform surgery, according to researchers at the SNM's 55th Ann ...

read more Combined positron emission tomography (PET) and computed tomography (CT) scanning of patients in the early stages of ovarian cancer can enable physicians to determine whether the cancer has spread to nearby lymph nodes without having to perform surgery, according to researchers at the SNM's 55th Ann read more Thu Jun 2008 Thu Jun 2008

New Study Shows Potential To Treat Or Prevent Viral Cancers

Categorie : Cancer / Oncology
A new study, presented at the SNM 55th Annual Meeting, shows that radioimmunotherapy (RIT) targeting viral antigens offers a novel option to treat - or even prevent - many viral cancers by targeting cancer cells expressing viral antigens or infected cells before they convert into malignancy. ...

read more A new study, presented at the SNM 55th Annual Meeting, shows that radioimmunotherapy (RIT) targeting viral antigens offers a novel option to treat - or even prevent - many viral cancers by targeting cancer cells expressing viral antigens or infected cells before they convert into malignancy. read more Thu Jun 2008 Thu Jun 2008

Decatur Memorial Hospital Becomes First In Illinois To Treat Cancer Patients With RapidArc? Radiotherapy Technology

Categorie : Cancer / Oncology
Decatur Memorial Hospital became the first medical center in Illinois, and the third in the United States, to treat a cancer patient using RapidArc? radiotherapy technology from Varian Medical Systems (NYSE: VAR). John Hosler, an 85-year-old prostate cancer patient, received his treatment in just un ...

read more Decatur Memorial Hospital became the first medical center in Illinois, and the third in the United States, to treat a cancer patient using RapidArc? radiotherapy technology from Varian Medical Systems (NYSE: VAR). John Hosler, an 85-year-old prostate cancer patient, received his treatment in just un read more Thu Jun 2008 Thu Jun 2008

After Genetic Testing People Obey Screening Recommendations Better

Categorie : Cancer / Oncology
When people know the results of genetic tests confirming they have inherited an increased risk of developing melanoma, they follow skin cancer screening recommendations more proactively - much like those who have already been diagnosed with the potentially deadly disease, according to results of a s ...

read more When people know the results of genetic tests confirming they have inherited an increased risk of developing melanoma, they follow skin cancer screening recommendations more proactively - much like those who have already been diagnosed with the potentially deadly disease, according to results of a s read more Thu Jun 2008 Thu Jun 2008

First Semiconductor-Based PET Scanner Demonstrates Potential To Aid In Early Diagnosis Of Disease

Categorie : Cancer / Oncology
Evaluations of the first-ever prototype positron emission tomography (PET) brain scanner that uses semiconductor detectors indicate that the scanner could advance the quality and spatial resolution of PET imaging, according to researchers at SNM's 55th Annual Meeting. The prototype scanner already h ...

read more Evaluations of the first-ever prototype positron emission tomography (PET) brain scanner that uses semiconductor detectors indicate that the scanner could advance the quality and spatial resolution of PET imaging, according to researchers at SNM's 55th Annual Meeting. The prototype scanner already h read more Thu Jun 2008 Thu Jun 2008

Patient's Own Infection-fighting T Cells Put Late-stage Melanoma Into Long-term Remission

Categorie : Cancer / Oncology
Researchers describe the first successful use of a human patient's cloned infection-fighting T cells as the sole therapy to put an advanced solid-tumor cancer into long-term remission. A team led by Cassian Yee, M.D., an associate member of the Clinical Research Division at Fred Hutchinson Cancer Re ...

read more Researchers describe the first successful use of a human patient's cloned infection-fighting T cells as the sole therapy to put an advanced solid-tumor cancer into long-term remission. A team led by Cassian Yee, M.D., an associate member of the Clinical Research Division at Fred Hutchinson Cancer Re read more Thu Jun 2008 Thu Jun 2008

BioInvent And ThromboGenics Announce A Strategic Alliance With Roche For TB-403, A Novel Anti-Cancer Antibody

Categorie : Cancer / Oncology
BioInvent International AB (STO:BINV) and ThromboGenics NV (Euronext Brussels: THR) announce that they have entered into a license agreement with Roche (SWX: ROG) for their jointly developed anti-cancer agent TB-403. TB-403 is a novel monoclonal antibody which blocks Placental Growth Factor (PIGF), ...

read more BioInvent International AB (STO:BINV) and ThromboGenics NV (Euronext Brussels: THR) announce that they have entered into a license agreement with Roche (SWX: ROG) for their jointly developed anti-cancer agent TB-403. TB-403 is a novel monoclonal antibody which blocks Placental Growth Factor (PIGF), read more Thu Jun 2008 Thu Jun 2008

First Patient Dosed In A Phase 1 Clinical Trial With Oral TRC102, An Inhibitor Of Chemotherapy Resistance, In Combination With Alimta®

Categorie : Cancer / Oncology
TRACON Pharmaceuticals, Inc., announced that the first cancer patient has been treated in a Phase 1 clinical trial with oral TRC102, a novel anti-cancer drug intended to reverse resistance to Alimta® chemotherapy by targeting a specific DNA repair pathway. "TRACON is taking the lead in developing o ...

read more TRACON Pharmaceuticals, Inc., announced that the first cancer patient has been treated in a Phase 1 clinical trial with oral TRC102, a novel anti-cancer drug intended to reverse resistance to Alimta® chemotherapy by targeting a specific DNA repair pathway. read more Thu Jun 2008 Thu Jun 2008

Talking About Sad, Bad And Difficult Issues In Cancer - ESMO And CRUK Partner On A Communication Skills Course For Oncologists

Categorie : Cancer / Oncology
An innovative course designed to help oncologists overcome communication barriers when talking to patients and their families will be organized in Buckinghamshire, UK from 18-20 June 2008 by the European Society for Medical Oncology (ESMO). ...

read more An innovative course designed to help oncologists overcome communication barriers when talking to patients and their families will be organized in Buckinghamshire, UK from 18-20 June 2008 by the European Society for Medical Oncology (ESMO). read more Thu Jun 2008 Thu Jun 2008

ChemGenex's Omacetaxine Demonstrates Activity In CML Patients Who Have Failed Therapy With Multiple Tyrosine Kinase Inhibitors

Categorie : Cancer / Oncology
ChemGenex Pharmaceuticals (ASX:CXS) (NASDAQ:CXSP) announced the presentation of positive preliminary results from a phase 2 study of omacetaxine mepesuccinate (formerly known as Ceflatonin®) in chronic myeloid leukemia (CML) patients who have failed therapy with at least two tyrosine kinase inhibit ...

read more ChemGenex Pharmaceuticals (ASX:CXS) (NASDAQ:CXSP) announced the presentation of positive preliminary results from a phase 2 study of omacetaxine mepesuccinate (formerly known as Ceflatonin®) in chronic myeloid leukemia (CML) patients who have failed therapy with at least two tyrosine kinase inhibit read more Thu Jun 2008 Thu Jun 2008

Absence Of Viable Carcinoma In Biopsies Performed Greater Than 1-Year Following Radiofrequency Ablation Of Renal Cortical Tumors

Categorie : Cancer / Oncology
ORLANDO, FL (UroToday.com) - Stern and colleagues report on their experience with tissue biopsy more than 1 year after radiofrequency ablation (RFA) of small renal masses. The study included 19 patients with 20 renal masses (17 pre-treatment proven RCC and 3 oncocytomas) that had previously undergon ...

read more ORLANDO, FL (UroToday.com) - Stern and colleagues report on their experience with tissue biopsy more than 1 year after radiofrequency ablation (RFA) of small renal masses. The study included 19 patients with 20 renal masses (17 pre-treatment proven RCC and 3 oncocytomas) that had previously undergon read more Thu Jun 2008 Thu Jun 2008

Newcastle Scientists Make Breakthrough In Treatment For Blood Cancer

Categorie : Cancer / Oncology
Newcastle University researchers, funded by leading blood cancer charity Leukaemia Research, have made significant progress in the development of improved treatments for chronic lymphocytic leukaemia, the commonest leukaemia in adults in the UK. ...

read more Newcastle University researchers, funded by leading blood cancer charity Leukaemia Research, have made significant progress in the development of improved treatments for chronic lymphocytic leukaemia, the commonest leukaemia in adults in the UK. read more Thu Jun 2008 Thu Jun 2008

<<< previous | 1 | 2 | 3 | 4 | 5 next >>>



     


Custom Search